 9 | |
| |
|
Strict Inclusion/Exclusion criteria were followed, and they were essentially the same ones used in numerous FDA studies of new drugs for symptomatic BPH. | |
|
9 | |
|
| |
|
Strict Inclusion/Exclusion criteria were followed, and they were essentially the same ones used in numerous FDA studies of new drugs for symptomatic BPH. | |